Recombinant Human VEGF-C (Cys156Ser) Protein

Images

 
There are currently no images for VEGF-C (752-VC).

Every product we sell is backed by Novus' 100% Guarantee. If you have used this product, please submit your images and reviews to earn reward points.

Product Details

Summary
Reactivity HuSpecies Glossary
Applications Binding Activity, Bioactivity

Order Details

View Available Formulations
Catalog# & Formulation Size Price

Recombinant Human VEGF-C (Cys156Ser) Protein Summary

Details of Functionality
Measured in a cell proliferation assay using HMVEC human microvascular endothelial cells. Marconcini, L. et al. (1999) Proc. Natl. Acad. Sci. USA 96:9671. The ED50 for this effect is 1-5 µg/mL. Measured by its binding ability in a functional ELISA. Immobilized Recombinant Human VEGF R3/Flt‑4 Fc Chimera (Catalog # 349-F4) at 5 µg/mL (100 µL/well) can bind  Recombinant Human VEGF‑C (Cys156Ser) with an apparent Kd <40 nM.
Source
Mouse myeloma cell line, NS0-derived human VEGF-C protein
Thr103-Arg227 (Cys156Ser), with a C-terminal 10-His tag
Accession #
N-terminal Sequence
Thr103
Protein/Peptide Type
Recombinant Proteins
Gene
VEGFC
Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Note
<0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

Theoretical MW
15.4 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
SDS-PAGE
22-24 kDa, reducing conditions
Publications
Read Publications using
752-VC in the following applications:

Packaging, Storage & Formulations

Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Buffer
Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Reconstitution Instructions
Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human VEGF-C (Cys156Ser) Protein

  • Flt4 ligand
  • Flt4-L
  • vascular endothelial growth factor C
  • Vascular endothelial growth factor-related protein
  • VEGFC
  • VEGF-C
  • VRPFLT4 ligand DHM

Background

Vascular endothelial growth factor C (VEGF-C) and VEGF-D constitute a subfamily of the angiogenic VEGF angiogenic factors (1). VEGF-C is synthesized as a 58 kDa molecule that consists of a VEGF homolgy domain (VHD) flanked by N- and C-terminal propeptides. The proprotein undergoes covalent homodimerization and stepwise proteolytic processing to generate ligands with increasing affinity for VEGF R3/Flt-4 (2-4). Fully processed VEGF-C containing just the 21 kDa VHD can additionally bind and activate VEGF R2/KDR/Flk-1 (2, 4). Fully processed human VEGF-C shares 98% amino acid sequence identity with mouse and rat VEGF-C. VEGF-C interactions with VEGF R3 are critical for lymphangiogenesis (5-8). VEGF-C and VEGF R3 are usually co-expressed at sites with lymphatic vessel sprouting, in the embryo, and in various pathological conditions. Over-expression of VEGF-C in tumor cells induces tumoral lymphatic hyperplasia, resulting in enhanced lymph flow and metastasis to regional lymph nodes (9-12). It also induces physiological and intratumoral neoangiogenesis and vessel sprouting through interactions with VEGF R2 (8, 13, 14).
  1. Chen, J.-C. et al. (2013) Int. J. Mol. Sci. 14:88.
  2. Joukov, V. et al. (1996) EMBO J. 15:290.
  3. Kukk, E. et al. (1996) Development 122:3829.
  4. Joukov, V. et al. (1997) EMBO J. 16:3898.
  5. Karkkainen, M. et al. (2004) Nat. Immunol. 5:74.
  6. Jeltsch, M. et al. (1997) Science 276:1423.
  7. Makinen, T. et al. (2001) Nat. Med. 7:199.
  8. Laakkonen, P. et al. (2007) Cancer Res. 67:593.
  9. Hoshida, T. et al. (2006) Cancer Res. 66:8065.
  10. Mandriota, S.J. et al. (2001) EMBO J. 20:672.
  11. Skobe, M. et al. (2001) Nat. Med. 7:192.
  12. Padera, T.P. et al. (2002) Science 296:1883.
  13. Tammela, T. et al. (2008) Nature 454:656.
  14. Cao, Y. et al. (1998) Proc. Natl. Acad. Sci. 95:14389.

Customers Who Viewed This Item Also Viewed...

AF743
Species: Mu
Applications: WB, Flow, CyTOF-ready
AF2125
Species: Mu
Applications: WB, IHC
AF644
Species: Mu
Applications: WB, Flow, IHC, CyTOF-ready, Neut
AF321
Species: Hu
Applications: WB, Flow, IHC, Block, CyTOF-ready
NB600-1015
Species: Mu, Hu(-)
Applications: WB, EM, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP, CyTOF-ready
NB100-689
Species: Hu, Mu, Rt
Applications: WB, Simple Western, IHC, IHC-P
AF3628
Species: Mu, Rt
Applications: WB, Flow, IHC, CyTOF-ready, ICC
NB110-41083
Species: Hu
Applications: WB, ChIP, ELISA
NB600-1071
Species: Mu, Rt
Applications: WB, ELISA, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP
NBP1-33050
Species: Hu, Mu
Applications: WB, ICC/IF, IHC, IHC-P
752-VC
Species: Hu
Applications: Binding Activity, Bioactivity

Publications for VEGF-C (752-VC)(14)

We have publications tested in 2 confirmed species: Human, Mouse.

We have publications tested in 2 applications: Bioassay, In Vivo.


Filter By Application
Bioassay
(7)
In Vivo
(6)
All Applications
Filter By Species
Human
(6)
Mouse
(8)
All Species
Showing Publications 1 - 10 of 14. Show All 14 Publications.
Publications using 752-VC Applications Species
JM Vieira, S Norman, C Villa Del, TJ Cahill, DN Barnette, M Gunadasa-R, LA Johnson, DR Greaves, CA Carr, DG Jackson, PR Riley The cardiac lymphatic system stimulates resolution of inflammation following myocardial infarction J. Clin. Invest., 2018;0(0):. 2018 [PMID: 29985167] (In Vivo, Mouse) In Vivo Mouse
YR Wen, JH Yang, X Wang, ZB Yao Induced dural lymphangiogenesis facilities soluble amyloid-beta clearance from brain in a transgenic mouse model of Alzheimer&#039;s disease Neural Regen Res, 2018;13(4):709-716. 2018 [PMID: 29722325] (Bioassay, Human) Bioassay Human
Louveau A, Smirnov I, Keyes T, Eccles J, Rouhani S, Peske J, Derecki N, Castle D, Mandell J, Lee K, Harris T, Kipnis J Structural and functional features of central nervous system lymphatic vessels. Nature, 2015;523(7560):337-41. 2015 [PMID: 26030524] (In Vivo, Mouse) In Vivo Mouse
Heishi T, Hosaka T, Suzuki Y, Miyashita H, Oike Y, Takahashi T, Nakamura T, Arioka S, Mitsuda Y, Takakura T, Hojo K, Matsumoto M, Yamauchi C, Ohta H, Sonoda H, Sato Y Endogenous angiogenesis inhibitor vasohibin1 exhibits broad-spectrum antilymphangiogenic activity and suppresses lymph node metastasis. Am. J. Pathol., 2010;176(4):1950-8. 2010 [PMID: 20133819] (In Vivo, Mouse) In Vivo Mouse
Chien MH, Ku CC, Johansson G, Chen MW, Hsiao M, Su JL, Inoue H, Hua KT, Wei LH, Kuo ML Vascular endothelial growth factor-C (VEGF-C) promotes angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3/JNK/AP-1 pathway. Carcinogenesis, 2009;30(12):2005-13. 2009 [PMID: 19825968] (Bioassay, Human) Bioassay Human
Kajiya K, Sawane M, Huggenberger R, Detmar M Activation of the VEGFR-3 pathway by VEGF-C attenuates UVB-induced edema formation and skin inflammation by promoting lymphangiogenesis. J. Invest. Dermatol., 2009;129(5):1292-8. 2009 [PMID: 19005491] (In Vivo, Mouse) In Vivo Mouse
Shin JW, Huggenberger R, Detmar M Transcriptional profiling of VEGF-A and VEGF-C target genes in lymphatic endothelium reveals endothelial-specific molecule-1 as a novel mediator of lymphangiogenesis. Blood, 2008;112(6):2318-26. 2008 [PMID: 18614759] (Bioassay, Human) Bioassay Human
Uzarski J, Drelles MB, Gibbs SE, Ongstad EL, Goral JC, McKeown KK, Raehl AM, Roberts MA, Pytowski B, Smith MR, Goldman J The resolution of lymphedema by interstitial flow in the mouse tail skin. Am. J. Physiol. Heart Circ. Physiol., 2008;294(3):H1326-34. 2008 [PMID: 18203849] (In Vivo, Mouse) In Vivo Mouse
Kilic N, Oliveira-Ferrer L, Neshat-Vahid S, Irmak S, Obst-Pernberg K, Wurmbach JH, Loges S, Kilic E, Weil J, Lauke H, Tilki D, Singer BB, Ergun S Lymphatic reprogramming of microvascular endothelial cells by CEA-related cell adhesion molecule-1 via interaction with VEGFR-3 and Prox1. Blood, 2007;110(13):4223-33. 2007 [PMID: 17761831] (Bioassay, Human) Bioassay Human
Huber S, Bruns CJ, Schmid G, Hermann PC, Conrad C, Niess H, Huss R, Graeb C, Jauch KW, Heeschen C, Guba M Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis. Kidney Int., 2007;71(8):771-7. 2007 [PMID: 17299523] (Bioassay, Human) Bioassay Human
Show All 14 Publications.

Reviews for VEGF-C (752-VC) (0)

There are no reviews for VEGF-C (752-VC). By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
  • Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
  • Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen
  • 1st to review with an image -- $50/€35/£30/$50 CAD/¥300 Yuan/¥5000 Yen

FAQs for VEGF-C (752-VC). (Showing 1 - 1 of 1 FAQs).

  1. I was wondering if you know of any blocking antibodies against IL-6 or VEGF-C that can be used in cell culture to quench these cytokines?
    • We have no antibodies that are currently known to show blocking antibodies to VEGF-C. Please see this link to our IL-6 antibodies with blocking/neutralizing activity can be found at this link.

Customers Who Bought This Also Bought

VEGF-C Antibody
NB110-61022

Contact Information

Product PDFs

Calculators

Concentration Calculator

The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.

=
÷

Review this Product

Be the first to review our Recombinant Human VEGF-C (Cys156Ser) Protein and receive a gift card or discount.

Bioinformatics

Gene Symbol VEGFC
Uniprot